Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 2D-to-3D Culture and Organoids 2020

Neeraja Idamakanti's Biography



Neeraja Idamakanti, Principal Scientist, Takeda Pharmaceuticals

Neeraja Idamakanti is Principal Scientist in the department of Drug Safety Research & Evaluation at Takeda. Neeraja’s main focus is investigative immunotoxicology. She is involved in developing de-risking strategies for molecules potential to cause immunotoxicity. Her interests include; cell biology, immunology, virology, genetherapy and immunotherapy. Before joining Takeda, Neeraja worked at Novartis for over 10 years. She obtained her BVSc (DVM) in Veterinary medicine from India and later she received MS in molecular virology from veterinary school at university of Saskatchewan, Canada.

Neeraja Idamakanti Image

In vitro Model For Immune Mediated Liver Injury Predictions

Thursday, 26 March 2020 at 15:15

Add to Calendar ▼2020-03-26 15:15:002020-03-26 16:15:00Europe/LondonIn vitro Model For Immune Mediated Liver Injury Predictions2D-to-3D Culture and Organoids 2020 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Despite recent advances in understanding of drug-induced liver injury (DILI), many aspects of its immune-mediated pathophysiology and clinical impact remain unclear. The inflammatory phenotype can be attributed to the innate or adaptive immune responses generated by infiltrating immune cells – which until now have never been successfully integrated into a functional 3D liver microtissue.  We developed immune mediated DILI model using human liver micro tissues with HLA matched PBMCs for prediction of clinical hepatotoxicity.


Add to Calendar ▼2020-03-25 00:00:002020-03-26 00:00:00Europe/London2D-to-3D Culture and Organoids 20202D-to-3D Culture and Organoids 2020 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com